Brief: MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
16/05/2024 13:06
May 16 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS STARTS PHASE 3 VELA PROGRAM OF
THE
NANOBODY® SONELOKIMAB IN PATIENTS WITH MODERATE-TO-SEVERE
HIDRADENITIS SUPPURATIVA
* MOONLAKE IMMUNOTHERAPEUTICS - TOPLINE PRIMARY ENDPOINT
READOUT
AT WEEK 16, TOGETHER WITH DATA ON OTHER ENDPOINTS, IS EXPECTED
AS OF MID-2025
Source text for Eikon: ID:nGNXbZPpPM
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial